Beyond CARs: New T-Cell Strategies Take Center Stage – OncLive
OncLive |
Beyond CARs: New T–Cell Strategies Take Center Stage
OncLive In the case of the 2 newly approved therapies, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), the transduction payload consists of single-chain variable fragments derived from an antibody that reacts against CD19. The transformed T … |
